Published in Scand J Gastroenterol on February 23, 2012
Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 1.49
Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol (2016) 1.43
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol (2015) 1.20
Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol (2013) 1.03
Fecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation. PLoS One (2014) 0.97
Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission. Gastroenterol Res Pract (2013) 0.94
Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis (2015) 0.90
Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci (2017) 0.85
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.84
Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One (2014) 0.83
Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol (2016) 0.81
Can fecal calprotectin better stratify Crohn's disease activity index? Ann Gastroenterol (2015) 0.81
Disease monitoring in inflammatory bowel disease. World J Gastroenterol (2015) 0.80
Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci (2014) 0.77
Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. Am J Gastroenterol (2016) 0.77
Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol (2015) 0.77
Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci (2016) 0.76
Crohn's disease Activity: Abdominal Computed Tomography Histopathology Correlation. Eur J Radiol Open (2016) 0.75
Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2014) 0.75
High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. Dig Dis Sci (2016) 0.75
The fecal microbiota as a biomarker for disease activity in Crohn's disease. Sci Rep (2016) 0.75
Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol (2016) 0.75
Microbiomarkers in inflammatory bowel diseases: caveats come with caviar. Gut (2017) 0.75
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology (2002) 2.99
Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology (2011) 2.51
Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol (2008) 2.33
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 2.22
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 2.17
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes (2007) 2.06
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2008) 1.69
IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis (2008) 1.66
Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy. Gastroenterology (2012) 1.57
Family and twin studies in inflammatory bowel disease. World J Gastroenterol (2006) 1.54
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. Endoscopy (2013) 1.50
Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int (2011) 1.48
Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2007) 1.24
Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm Bowel Dis (2008) 1.20
Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol (2010) 1.19
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology (2010) 1.18
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology (2010) 1.17
Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer (2002) 1.16
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis (2012) 1.13
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (2005) 1.12
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
Esophageal morbidity and function in adults with repaired esophageal atresia with tracheoesophageal fistula: a population-based long-term follow-up. Ann Surg (2010) 1.07
IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet (2009) 1.06
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. Inflamm Bowel Dis (2009) 1.06
Extraintestinal Clostridium difficile infections. Clin Infect Dis (2013) 1.01
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis (2011) 0.99
Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol (2013) 0.99
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis (2014) 0.97
Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One (2012) 0.94
Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis (2011) 0.91
Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol (2013) 0.90
Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis (2010) 0.90
Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol (2012) 0.90
Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis (2009) 0.89
Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis (2010) 0.89
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol (2013) 0.88
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol (2005) 0.88
Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol (2007) 0.86
Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual Life Res (2009) 0.85
Measuring gastric emptying: comparison of 13C-octanoic acid breath test and scintigraphy. Dig Dis Sci (2006) 0.85
Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis (2012) 0.85
A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohns Colitis (2012) 0.85
Patient-controlled sedation with propofol and remifentanil for ERCP: a randomized, controlled study. Gastrointest Endosc (2011) 0.85
Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol (2011) 0.84
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet (2012) 0.84
Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis (2010) 0.83
Radiation exposure during nasojejunal intubation for MRI enteroclysis. Scand J Gastroenterol (2012) 0.83
Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis (2014) 0.83
Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis (2014) 0.83
Capsule endoscopy in pediatric patients: technique and results in our first 100 consecutive children. Scand J Gastroenterol (2011) 0.83
The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol (2012) 0.82
Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. Eur J Hum Genet (2003) 0.82
Clinical value of ultrasound in the evaluation of dyspepsia in primary health care. Scand J Gastroenterol (2005) 0.82
Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol (2012) 0.82
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One (2012) 0.82
The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants. Am J Gastroenterol (2002) 0.82
Novel CARD15/NOD2 mutations in Finnish patients with Crohn's disease and their relation to phenotypic variation in vitro and in vivo. Inflamm Bowel Dis (2008) 0.81
Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology (2010) 0.80
Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. Scand J Gastroenterol (2011) 0.79
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol (2014) 0.79
In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. ISRN Gastroenterol (2012) 0.79
Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. Alcohol Clin Exp Res (2010) 0.79
[Hypopituitarism and hepatitis as complications of nephropathia epidemica]. Duodecim (2002) 0.78
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology (2008) 0.78
Screening of tumor necrosis factor receptor-associated factor 6 as a candidate gene for inflammatory bowel disease. Scand J Gastroenterol (2006) 0.78
Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling. PLoS One (2013) 0.78
Detection of muramyl dipeptide-sensing pathway defects in monocytes of patients with Crohn's disease using phospho-specific whole blood flow cytometry. Scand J Clin Lab Invest (2013) 0.78
Helsinki alert of biodiversity and health. Ann Med (2015) 0.78
Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology (2010) 0.78
Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. Qual Life Res (2010) 0.77
A patient with ulcerative colitis and an unusual rash. Gastroenterology (2010) 0.77